OR WAIT null SECS
Robert A. Figlin, MD, spoke with CancerNetwork® about emerging second-line therapies as the paradigm of first-line treatment evolves for patients with metastatic clear cell renal cell carcinoma.
This week, CancerNetwork® examined an article from the June issue of the journal ONCOLOGY® titled “Second-Line Therapies in the Changing Landscape of First-Line Therapies for Metastatic Clear Cell Renal Cell Cancer” by speaking with one of the authors, Robert A. Figlin, MD.
Figlin, who is a professor of medicine and biomedical sciences, Steven Spielberg Family Chair in Hematology-Oncology, and deputy director of Cedars-Sinai Cancer at the Cedars-Sinai Medical Center in Los Angeles, California, spoke about the evolving treatment paradigm of metastatic clear cell renal cell carcinoma, specifically how the shifting landscape of first-line therapies has impacted second-line therapeutic strategies. He discussed standard therapeutic strategies in this space, such as the use of immunotherapy and tyrosine kinase inhibitors, and how new data affect where these agents fit in to patient care.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.